Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2018

View Archived Issues

HIWI2 piRNA binding protein is involved in the pathogenesis of proliferative diabetic retinopathy

Faron initiates phase I/II study of FP-1305 in advanced solid tumors

New rat models of ALS better capture human disease pathology

Characterization of new murine model of polyhydramnios-megalencephaly and symptomatic epilepsy

SEP-363856 demonstrates safety and efficacy in phase II study in patients with schizophrenia

Staten Biotechnology, Novo Nordisk enter collaboration and option agreement in hypertriglyceridemia

Resolvin receptor analogues limit inflammation

HER mutations can cause ER resistance

Recombinant measles virus expressing NIS demonstrates antitumor activity in metastatic breast cancer

Modulation of brain dopamine release by Takeda's GPCR139 agonist TAK-041

Preclinical data presented for CYT-0851

CB-103 demonstrates synergistic activity with fulvestrant in ER-positive breast cancer

Reduced RNA editing links different forms of autism

Cancer Research Technology patents BCL-6 inhibitors

Abbisko Therapeutics divulges new CSF-1R inhibitors

Chengdu Euthare Therapeutics synthesizes CDK4 and CDK6 inhibitors

Taisho Pharmaceutical discloses bacterial LpxC inhibitors

Araxes Pharma identifies new mutant KRAS inhibitors

Kineta and Pfizer collaborate to develop RIG-I agonist immunotherapies for cancer

Keytruda approved in Europe as adjuvant therapy for adults with resected stage III melanoma

Topline results presented from phase I study of XCUR-17 in chronic plaque psoriasis

BeiGene initiates two global phase III studies of tislelizumab

Phase III obesity registration trial of tesofensine meets primary and secondary endpoints

Initiation of pivotal phase III program of TWIN for acne vulgaris

Rakuten Aspyrian opens enrollment in phase III trial of ASP-1929 for head and neck cancer

China becomes first country to approve roxadustat

Ayala initiates phase II study of AL-101 in adenoid cystic carcinoma with Notch activated mutations

Alkahest reports promising data from two phase IIa studies of AKST-4290 in wet AMD

Ovid Therapeutics presents phase Ib/IIa data for OV-935 in adults with rare epilepsies

Aclaris offers update on clinical trials of JAK1/3 inhibitors ATI-502 and ATI-501

Achillion reports update on factor D inhibitor programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...